Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TheraBionic with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT05776524Phase 2Recruiting
- Sponsor
- Therabionic
- Start
- Jun 2023
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Therabionic. Primary endpoint: Overall Survival at 6 months. Started Jun 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05776524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776524.